| 1 |
30190369 | A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. | 2019 Jan 1 |
1 |
| 2 |
31471309 | Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. | 2019 Oct 15 |
1 |
| 3 |
27659533 | Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). | 2016 Nov 8 |
1 |
| 4 |
20166888 | Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. | 2010 Jun |
2 |
| 5 |
20962354 | Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. | 2010 Nov |
1 |